Formulation transdermal delivery

Topical Formulations. Topical formulations by their very nature are usually multicomponent, and it is not surprising that neural networks have been applied to deal with this complexity. The first work was performed on hydrogel formulations containing anti-inflammatory drugs in Japan in 1997 [57], followed up by further studies in 1999 [58] and in 2001 [59]. Lipophilic semisolid emulsion systems have been studied in Slovenia [60, 61] and transdermal delivery formulations of melatonin in Florida [62]. In all cases, the superiority of neural networks over conventional statistics has been reported. 

In addition to traditional dermal and transdermal delivery formulations, such as creams, ointments, gels, and patches, several other systems have been evaluated. In the pharmaceutical semisolid and liquid formulation area,these include sprays, foams, multiple emulsions, microemulsions, liposomal formulations, transfersomes, niosomes, ethosomes, cyclodextrins, glycospheres, dermal membrane structures, and microsponges. Many of these novel systems use vesicles to modulate drug delivery. Novel transdermal... 

Oleyl alcohol is mainly used in topical pharmaceutical formulations and has been used in transdermal delivery formulations. It has been utilized in the development of biodegradable injectable thermoplastic oligomers, and in aerosol formulations of insulin and albuterol. ... 

Current androgenic formulations for TRT largely are restricted to injectable formulations of testosterone esters, transdermal delivery formulations (scrotal or nonscrotal patches or gel), or buccal testosterone. Marketed injectable forms of testosterone esters (e.g., testosterone enanthate, propionate, or cypionate) produce undesirable fluctuations in testosterone blood levels, with supraphysiological concentrations early and subphysiological levels toward the end of the period before the next injection. These fluctuations provide an unsatisfactory benefits profile and, in some cases, undesired side effects. Skin patches provide a better blood level profile of testosterone, but skin irritation and daily application limit the usefulness and acceptability of this form of therapy. Oral... 

The MAO-B inhibitor, l-deprenyl, has been approved by the FDA for use in Parkinson s disease. At the lower dose range, it does not interact with tyramine. As mentioned earlier, there is preliminary evidence of antidepressant efficacy for a transdermal delivery system for selegiline. This formulation does not interact with tyramine to produce a hypertensive crisis (181). 

Transdermal delivery of certain APIs is now common for the treatment of some medical conditions, and there are several excipients that are promoted as transdermal penetration enhancers. One of the earlier materials developed was laurocapram (Azone ). There is a detrimental interaction between laurocapram and mineral oil (liquid paraffin) whereby when both are included in the same formulation, the skin penetration-enhancing properties of laurocapram are lost. Such interactions have implications for extemporaneous mixing of different cream and ointment formulations in the pharmacy. 

The lack of significant impact of CPEs on transdermal delivery vehicles is related to the inherent nonspecific activity of CPEs in the different strata of the skin, as discussed earlier. This limitation may be overcome by utilization of mixtures of CPEs. Research has already shown that binary mixtures of CPEs provide increased permeation enhancement as well as increased safety compared to single enhancers. Such unique chemical combinations, called synergistic combinations of penetration enhancers or SCOPE formulations, offer new opportunities in transdermal drug delivery (46). 

The discrete concentrations in the set C may be selected based on different considerations specific to the particular application of the formulation. For example, for transdermal delivery applications, we initially selected concentrations in a narrow range of 0% to 2%wt/vol. 

Writing down such mathematical expressions provides us with the experimentation volume required to completely characterize a test pool of components in multicomponent formulations. It also provides a systematic approach for design of experiments and data interpretation. Using the above mathematical expressions, we can estimate the number of experiments required to characterize a test pool of candidate enhancers for transdermal drug delivery formulations as a function of the size of the test pool. 

Funke, A.P., et al. 2002. Transdermal delivery of highly lipophilic drugs In vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. Pharm Res 19 661. 

Chemical PEs have recently been studied for increasing transdermal delivery of ASOs or other polar macromolecules [35]. Chemically induced transdermal penetration results from a transient reduction in the barrier properties of the stratum corneum. The reduction may be attributed to a variety of factors such as the opening of intercellular junctions due to hydration [36], solubilization of the stratum corneum [37, 38], or increased lipid bilayer fluidization [39, 40]. Combining various surfactants and co-solvents can be used to achieve skin penetration, purportedly resulting in therapeutically relevant concentrations of ASO in the viable epidermis and dermis [41]. In summary, it appears feasible to deliver ASO to the skin using a number of different delivery techniques and formulations. 

A description of transdermal drug delivery has been produced which is based on the physicochemical properties of the permeant. At this time transdermal delivery is limited to the administration of potent drugs. Higher doses may be accessible if penetration enhancers are incorporated into the formulation. The kinetic model shows what properties these should have and that they are a function of the physico-chemical properties of the drug. Various loss processes, e.g. microbial biotransformation, skin enzyme metabolism can be identified but cannot, as yet, be quantified. 

PG fluxes into the receptor chamber following delivery across hairless mouse skin from formulations (a) and (b) are shown in Figures 3 and 4, respectively. PG association with EPC liposomes [(b)] lowers by one-half the transdermal delivery of the drug when compared to the free patch [(a)]. 

These testosterone systems illustrate two different approaches to solve the problem of inadequate percutaneous absorption rate. In the former case, the patch must be applied to the body s most permeable skin site, the scrotum (which has been shown to be at least five times more permeable than ary other site). In the latter, the difficulty is resolved by creating a transdermal formulation which includes excipients to reduce barrier function. Neither solution is ideal scrotal application is clearly not preferred from a patient compliance standpoint on the other hand, permeation enhancers, by their very nature, tend to be irritating (and the more effective they are, the greater the irritation they provoke). This general problem, which presently limits the application of transdermal delivery, is now discussed in more detail. 

Localized tissue irritation can be seen from the intramuscular (IM) route. This is especially an issue when the formulation pH differs from the pH of the surrounding tissue or when precipitation of poorly soluble drugs occurs. Incorrect administration of IM injections is probably the most important factor that causes local adverse effects. Local skin irritation can also be seen with transdermal delivery systems due to the alcohols, nonionic surfactants, and adhesives. 

---